Please login to the form below

Not currently logged in

Agility Award in Pharma Market Excellence

Sponsored by

Back to Results


Accord’s Agility Ensures Medicines Supply During COVID-19

by Accord Healthcare Ltd
with support from Alexa Forbes Consulting Ltd

Summary of work

As demand spiked, export bans came into force and borders were closed, the supply of critical medicines became a serious logistical and management challenge during the height of the COVID-19 pandemic. As a leading supplier of medicines, a vast number of healthcare providers, intensive care units (ICU) and patients were relying on Accord to provide life-saving medicines at a time of desperate need.

Accord led the charge undertaking a programme of in-depth literature scanning and engagement with leading ICU physicians to build an understanding of the evolving clinical research base. This was translated into focused activities to ensure rapid provision of repurposed medicines both to trials and the clinical front line, winning many plaudits from health systems and workers. It facilitated the construction of a COVID-19 pharmacopeia, that was shared with the industry to ensure multiple producers were focusing their production on the medicines of greatest likely need. The Accord team developed an in-house epidemiological demand model, which was subsequently used pan-industry to quantify the likely surge in ICU medicines need.

Using this knowledge, swift decisions were taken to export raw chemicals out of Asia just hours before export bans were implemented. These early actions meant that Accord was able to meet the growing demand for critical medicines, in addition to donating millions of tablets into trials. Whilst prioritising medicines supply, internal communications increased dramatically to ensure the workforce felt not only connected but truly part of the fight, maintaining attendance and output.

Judges' comments

Accord’s reaction to the COVID-19 pandemic and their quick thinking was extremely forward thinking. The challenges were well documented, and their plan was executed impressively, with an impressive scale-up which resulted in extra doses of medicines before export bans came into place. This pre-emptive thinking was bold and worthwhile.


“Switch 4 Them” - Protecting Vulnerable Patients During a Pandemic - by Bayer

Supporting Alcohol Teams through the Global COVID19 Pandemic - by Kyowa Kirin
with support from Ann Taylor, Adam Winstock, Liz Gilligan, Adrian Brown, Anthony Gartland

Launching Takhzyro: Re-defining the Rules for Treatment Initiation - by Takeda UK
with support from Makara Health

Entyvio® (vedolizumab) Subcutaneous Launch: Not Making a Drama Out of a Crisis - by Takeda UK Ltd
with support from Aurora Healthcare Communications

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022